B. Riley Securities analyst Craig Ellis maintains Semtech (NASDAQ:SMTC) with a Buy and lowers the price target from $108 to $83.
United Therapeutics-MannKind’s Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
United Therapeutics Corporation (NASDAQ: UTHR) has